Even those who supported the F.D.A.’s approval of the controversial new drug said authorizing it for anyone with Alzheimer’s disease was much too broad.
Published: June 22, 2021 at 04:55AM
from NYT Health https://ift.tt/2TSOAUm
Even those who supported the F.D.A.’s approval of the controversial new drug said authorizing it for anyone with Alzheimer’s disease was much too broad.
Published: June 22, 2021 at 04:55AM
from NYT Health https://ift.tt/2TSOAUm